ReviewJournal of controlled release : official journal of the Controlled Release Society2021
Pulmonary siRNA delivery for lung disease: Review of recent progress and challenges.
Review in Journal of controlled release : official journal of the Controlled Release Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 72 citations in OpenAlex.
- Nanocarrier-Mediated Drug Delivery via Inhalational Route for Lung Cancer Therapy: A Systematic and Updated Review.AAPS PharmSciTech · 2024Pooled it
- LncRNA SNHG14 drives alveolar inflammation in bronchopulmonary dysplasia via DNMT3a-mediated epigenetic silencing of miR-214-3p.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026Article
- Penetratin Decoration Increases RNAi Silencing Effects of Polymeric Carriers.Chemistry of materials : a publication of the American Chemical Society · 2026Article
- RNA-Loaded Nanoparticles for Targeted Lung Delivery.Biomedicines · 2026Review
- Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastases.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- Beyond Variant Evolution: Structurally and Functionally Conserved Regions in the 5'UTR of SARS-CoV-2 as Resilient Antiviral Targets.Biomedicines · 2026Article
- Inhalable stem cell-derived artificial nanovesicles for targeted siRNA delivery to effectively alleviate asthma symptoms.Asian journal of pharmaceutical sciences · 2026Article
- RDYH58 functional exosomes targeting myofibroblasts loaded with siFKBP10 for inhibition of collagen biosynthesis and secretion of IPF.Acta pharmaceutica Sinica. B · 2025Article
- Nebulized macrophage membrane-engineered triptolide liposomes for Siglec-10/CD24-mediated therapeutic targeting in lung cancer.International journal of pharmaceutics: X · 2025Article
- Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.Bioactive materials · 2025Review
- Robust peptide/RNA complexes prepared with microfluidic mixing for pulmonary delivery by nebulisation.Drug delivery and translational research · 2025Article
- Inhaled non-viral delivery systems for RNA therapeutics.Acta pharmaceutica Sinica. B · 2025Review
- Analysis of Polymer/siRNA Nanoparticle Efficacy and Biocompatibility in 3D Air-Liquid Interface Culture Compared to 2D Cell Culture.Pharmaceutics · 2025Article
- Martini compatible coarse-grained model of polyethylenimine for pulmonary gene delivery.Scientific reports · 2025Article
- Recent Advancement in Inhaled Nano-drug Delivery for Pulmonary, Nasal, and Nose-to-brain Diseases.Current drug delivery · 2025Review
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Efficient Nebulization and Pulmonary Biodistribution of Polymeric Nanocarriers in an Acute Lung Injury Preclinical Model.Small science · 2024Article
- Pulmonary fibroblast-specific delivery of siRNA exploiting exosomes-based nanoscaffolds for IPF treatment.Asian journal of pharmaceutical sciences · 2024Article
- Expanding RNAi to Kidneys, Lungs, and Spleen via Selective ORgan Targeting (SORT) siRNA Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024Article
- Realveolarization with inhalable mucus-penetrating lipid nanoparticles for the treatment of pulmonary fibrosis in mice.Science advances · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Lung diseases are a leading cause of mortality worldwide and there exists urgent need for new therapies. Approval of the first siRNA treatments in humans has opened the door for further exploration of this therapeutic strategy for other disease states. Pulmonary delivery of siRNA-based biopharmaceuticals offers the potential to address multiple unmet medical needs in lung-related diseases because of the specific physiology of the lung and characteristic properties of siRNA. Inhalation-based siRNA delivery designed for efficient, targeted delivery to specific cells within the lung holds great promise. Efficient delivery of siRNA directly to the lung, however, is relatively complex. This review focuses on the barriers that impact pulmonary siRNA delivery and successful recent approaches to advance this field forward. We focus on the pulmonary barriers that affect siRNA delivery, the disease-dependent pathological changes and their role in pulmonary disease and impact on siRNA delivery, as well as the recent development on the pulmonary siRNA delivery systems.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.